Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$861M |
| 2 |
Apple
AAPL
|
+$417M |
| 3 |
JPMorgan Chase
JPM
|
+$350M |
| 4 |
T-Mobile US
TMUS
|
+$337M |
| 5 |
Aon
AON
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$603M |
| 2 |
Charter Communications
CHTR
|
+$504M |
| 3 |
Fidelity National Information Services
FIS
|
+$496M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$429M |
| 5 |
Baxter International
BAX
|
+$362M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 3.54% |
| 2 | Technology | 3.36% |
| 3 | Financials | 2.95% |
| 4 | Consumer Discretionary | 2.92% |
| 5 | Industrials | 2.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
8776
CALL
Galectin Therapeutics
GALT
$347M
| $107K | ﹤0.01% |
34,900
-6,000
| -15% | -$15.1K |
|
|
TRTX
8777
CALL
TPG RE Finance Trust
TRTX
$609M
| $107K | ﹤0.01% |
12,400
-14,200
| -53% | -$103K |
|
8778
Metallus
MTUS
$904M
| $107K | ﹤0.01% |
27,524
-36,323
| -57% | -$121K |
|
|
SEI
8779
PUT
Solaris Energy Infrastructure
SEI
$4.17B
| $107K | ﹤0.01% |
14,400
-1,200
| -8% | -$7.85K |
|
|
BFX
8780
PUT
DELISTED
BowFlex Inc.
BFX
| $107K | ﹤0.01% |
11,500
-5,500
| -32% | -$33.3K |
|
|
EVFM
8781
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| $107K | ﹤0.01% |
2,514
+1,084
| +76% | +$73.1K |
|
8782
CALL
Arlo Technologies
ARLO
$1.54B
| $106K | ﹤0.01% |
41,000
+12,300
| +43% | +$29.7K |
|
8783
Amplify Lithium & Battery Technology ETF
BATT
$124M
| $106K | ﹤0.01% |
11,728
-69,542
| -86% | -$566K |
|
8784
CALL
KRONOS Worldwide
KRO
$975M
| $106K | ﹤0.01% |
+10,200
| New | +$95.7K |
|
8785
CALL
INNOVATE Corp
VATE
$109M
| $106K | ﹤0.01% |
+3,180
| New | +$89.9K |
|
8786
PUT
VirnetX Holding Corp
VHC
$62.8M
| $106K | ﹤0.01% |
815
-2,895
| -78% | -$354K |
|
|
ATRS
8787
PUT
DELISTED
Antares Pharma, Inc.
ATRS
| $106K | ﹤0.01% |
38,600
-14,100
| -27% | -$39.3K |
|
8788
CALL
DNOW Inc
DNOW
$2.97B
| $105K | ﹤0.01% |
+12,200
| New | +$83.8K |
|
8789
PUT
Prothena Corp
PRTA
$455M
| $105K | ﹤0.01% |
10,000
-5,900
| -37% | -$65.6K |
|
|
CHS
8790
PUT
DELISTED
Chicos FAS, Inc.
CHS
| $105K | ﹤0.01% |
76,200
+10,400
| +16% | +$14.1K |
|
|
XONE
8791
CALL
DELISTED
The ExOne Company
XONE
| $105K | ﹤0.01% |
12,300
-17,600
| -59% | -$140K |
|
|
ICAD
8792
PUT
DELISTED
iCAD Inc
ICAD
| $104K | ﹤0.01% |
10,400
-9,900
| -49% | -$107K |
|
8793
CALL
Solid Biosciences
SLDB
$986M
| $104K | ﹤0.01% |
2,373
-1,854
| -44% | -$77K |
|
|
NPKI
8794
NPK International
NPKI
$1.21B
| $104K | ﹤0.01% |
46,634
-47,741
| -51% | -$80.8K |
|
|
AVID
8795
PUT
DELISTED
Avid Technology Inc
AVID
| $104K | ﹤0.01% |
14,300
+800
| +6% | +$5.28K |
|
|
MGI
8796
PUT
DELISTED
MoneyGram International, Inc. New
MGI
| $104K | ﹤0.01% |
32,500
+6,300
| +24% | +$13.6K |
|
|
JNCE
8797
PUT
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $104K | ﹤0.01% |
15,000
-8,000
| -35% | -$43.2K |
|
8798
Ocugen
OCGN
$458M
| $103K | ﹤0.01% |
465,972
+338,774
| +266% | +$102K |
|
|
DNR
8799
CALL
DELISTED
Denbury Resources, Inc.
DNR
| $103K | ﹤0.01% |
374,500
+114,800
| +44% | +$34.5K |
|
8800
PUT
Immersion
IMMR
$249M
| $102K | ﹤0.01% |
16,300
-5,000
| -23% | -$32.3K |
|
Similar funds
Ken Griffin's Q2 2020 Portfolio in Review
As of Q2 2020, Ken Griffin held 11,014 positions worth $280B, up 26% from $222B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Ken Griffin withdrew a net $9.91B in Q2 2020, closing 1,324 positions and reducing 3,586 holdings. Its most notable exit was Allergan plc, an estimated $603M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 3.5% of assets, down from 4.1% a quarter earlier, followed by Technology and Financials.
Against the trend, Ken Griffin opened a new position in Becton Dickinson worth $266M.
- Ken Griffin's largest Q2 2020 buy was Becton Dickinson: 1,140,373 shares worth $266M.
- Ken Griffin added most to Amazon in Q2 2020, an estimated $861M increase.
- Ken Griffin's biggest Q2 2020 reduction was Charter Communications, cutting an estimated $504M.
- Ken Griffin fully exited Allergan plc in Q2 2020, selling an estimated $603M.
- Ken Griffin's ten largest holdings make up 32% of its $280B portfolio in Q2 2020.
- Ken Griffin opened 1,506 new positions and closed 1,324 in Q2 2020.
- Ken Griffin's portfolio value rose 26% quarter-over-quarter to $280B.
Based on Citadel Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.